Chadé Severin

Chadé Severin

Partner, Mergers and Acquisitions
Chadé Severin focuses her practice on mergers, acquisitions and other transactions for private and public companies in the pharmaceutical, life sciences and technology industries.


Ms. Severin’s representations include:

  • Stemline Therapeutics in its sale to Menarini Group for up to $677 million;
  • Gilead Sciences in its $4.9 billion acquisition of Forty Seven;
  • ArQule in its sale to Merck for $2.7 billion;
  • Carbonite in its sale to OpenText for $1.42 billion;
  • Achillion in its sale to Alexion for up to $1.225 billion;
  • Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion;
  • Array BioPharma in its $11.4 billion sale to Pfizer;
  • Carbonite in its $618.5 million acquisition of Webroot;
  • Armstrong Flooring Inc. in the sale of its wood flooring business to American Industrial Partners;
  • Juno Therapeutics in its $9 billion acquisition by Celgene;
  • Ultragenyx in its successful topping bid for Dimension Therapeutics;
  • Gilead in its $11.9 billion acquisition of Kite Pharma;
  • Merrimack Pharmaceuticals in its asset sale to Ipsen S.A. for up to $1.025 billion;
  • Tobira Therapeutics in its acquisition by Allergan for up to $1.7 billion; and
  • Qlik Technologies in its $3 billion acquisition by Thoma Bravo.

Before attending law school, Ms. Severin worked for Google at its California headquarters.



  • J.D., Columbia Law School, 2013
  • B.A., Stanford University, 2007


  • Massachusetts
  • New York

Chadé Severin

Partner, Mergers and Acquisitions